Ata Gh Pregnancy Discontinuation

---
name: ata-gh-pregnancy-discontinuation
description: Suggests discontinuing growth hormone (GH) replacement during pregnancy due to lack of clear evidence for efficacy or safety and placental GH production. Triggers include managing a pregnant patient on GH replacement.
---

# Discontinue growth hormone replacement during pregnancy

## STEP 1 — Gather Information
Confirm pregnancy via clinical assessment or laboratory test (e.g., serum hCG, ultrasound) and document current GH replacement dose and frequency. **Action:** Record pregnancy status and GH prescription.

## STEP 2 — Rule In / Rule Out
If the patient is pregnant and currently prescribed GH replacement, rule in for discontinuation; otherwise, rule out and maintain current therapy. **Decision:** Proceed to discontinuation if ruled in.

## STEP 3 — Classify or Stratify
Assess for any acute endocrine emergencies (e.g., hypoglycemia, hypotension) that might warrant caution; if none, classify as suitable for discontinuation. **Action:** Classify patient as appropriate for GH cessation.

## STEP 4 — Decide
Discontinue GH replacement immediately. Advise patient to report any new symptoms (e.g., fatigue, weakness) and arrange follow‑up in 4–6 weeks to reassess clinical status. **Decision:** Stop GH and plan monitoring.

## Clinical Guardrails / Mimics / Pitfalls
Do not continue GH based on theoretical benefit; placental GH production may mask deficiency. Avoid mistaking normal pregnancy symptoms (fatigue, edema) for GH deficiency worsening. Do not delay discontinuation awaiting symptom improvement without evidence. Monitor other pituitary axes (thyroid, cortisol) as their needs may change in pregnancy.

## Concrete Clinical Example
A 28‑year‑old woman with adult GH deficiency on 0.3 mg/day GH presents at 12 weeks gestation. After confirming pregnancy, GH is stopped. She reports no worsening of fatigue or body composition changes at 20‑week follow‑up.

**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118